PRIVATE SECTOR ADVISORY BOARD COVID-19 RESPONSES: JOHNSON & JOHNSON
Our Private Sector Advisory Board have responded to challenges facing the healthcare sector with smart and timely interventions.
ARC’s Private Sector Advisory Board is a panel of representatives from the private sector who share their experiences in supply chain systems with the public sector. This board seeks to advance the thinking on private sector engagement in public health in Africa while exploring new models and approaches that have the highest return on investment.
In the face of the coronavirus epidemic, many of the companies represented on this board have responded to challenges facing the healthcare sector with smart and timely interventions. We’re sharing some of these here, starting with Johnson & Johnson.
Johnson & Johnson: supply chain sustainability and vaccine development
Johnson & Johnson is the world’s largest and most broadly based healthcare company and believes that good health is the foundation of vibrant lives, thriving communities and forward progress. For more information on the company and its COVID-19 response, visit the Johnson & Johnson newsroom.
Johnson & Johnson has been working to ensure its own supply chain, which produces everything from contact lenses to prescription medications to fever reducers, is currently holding steady and meeting patient needs. Johnson & Johnson has robust business continuity plans in place across its global supply chain network to prepare for unforeseen events and to meet the needs of the patients and consumers who depend on its products. These steps include maintaining key inventory at major distribution centres away from high-risk areas and working with external suppliers to support their preparedness plans.
The second thing the company is doing is working on a vaccine. Johnson & Johnson is mobilising the resources of its Janssen Pharmaceutical Companies in response to the outbreak to develop a possible preventive vaccine candidate against SARS-CoV-2, leveraging Janssen’s AdVac® and PER.C6® technology, which provide the ability to rapidly upscale production of the optimal vaccine candidate.
These are the same technologies that were used in the development and manufacturing of Janssen’s investigational Ebola vaccine, which is currently deployed in the Democratic Republic of the Congo and Rwanda, and were also used to construct the Company’s Zika, RSV and HIV vaccine candidates.
The company is also reviewing known pathways in coronavirus pathophysiology to determine whether previously tested medicines can be used to help patients survive COVID-19 and reduce the severity of disease in non-lethal cases.
Johnson & Johnson has also been donating critical health supplies to help first responders, including a million masks, 48 000 bottles of isopropyl alcohol (a medical sanitiser), as well as goggles, protective suits, thermometers and respirators. The company also contributed 1 million CNY to the Chinese Red Cross Foundation.